18F-FDG Uptake in Breast Cancer Correlates with Immunohistochemically Defined Subtypes

Overview

Journal Eur Radiol

Specialty Radiology

Date 2013 Oct 8

PMID 24097303

Citations 52

Authors

Hye Ryoung Koo

Jeong Seon Park

Keon Wook Kang

Nariya Cho

Jung Min Chang

Min Sun Bae

Won Hwa Kim

Su Hyun Lee

Mi Young Kim

Jin You Kim

Mirinae Seo

Woo Kyung Moon

Affiliations

Soon will be listed here.

Abstract

Objectives: To determine whether a correlation exists between maximum standardized uptake value (SUVmax) on (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) and the subtypes of breast cancer.

Methods: This retrospective study involved 548 patients (mean age 51.6 years, range 21-81 years) with 552 index breast cancers (mean size 2.57 cm, range 1.0-14.5 cm). The correlation between (18)F-FDG uptake in PET/CT, expressed as SUVmax, and immunohistochemically defined subtypes (luminal A, luminal B, human epidermal growth factor receptor 2 (HER2) positive and triple negative) was analyzed.

Results: The mean SUVmax value of the 552 tumours was 6.07 ± 4.63 (range 0.9-32.8). The subtypes of the 552 tumours were 334 (60%) luminal A, 66 (12%) luminal B, 60 (11%) HER2 positive and 92 (17%) triple negative, for which the mean SUVmax values were 4.69 ± 3.45, 6.51 ± 4.18, 7.44 ± 4.73 and 9.83 ± 6.03, respectively. In a multivariate regression analysis, triple-negative and HER2-positive tumours had 1.67-fold (P < 0.001) and 1.27-fold (P = 0.009) higher SUVmax values, respectively, than luminal A tumours after adjustment for invasive tumour size, lymph node involvement status and histologic grade.

Conclusion: FDG uptake was independently associated with subtypes of invasive breast cancer. Triple-negative and HER2-positive breast cancers showed higher SUVmax values than luminal A tumours.

Key Points: • (18) F-FDG PET demonstrates increased tissue glucose metabolism, a hallmark of cancers. • Immunohistochemically defined subtypes appear significantly associated with FDG uptake (expressed as SUV max ). • Triple-negative tumours had 1.67-fold higher SUV max values than luminal A tumours. • HER2-positive tumours had 1.27-fold higher SUV max values than luminal A tumours.

Citing Articles

Evaluation of prognostic risk factors of triple-negative breast cancer with F-FDG PET/CT parameters, clinical pathological features and biochemical indicators.

Zhu L, Yang X, Zhang J, Wang S, Wang Y, Wan X Front Cell Dev Biol. 2024; 12:1421981.

PMID: 39296933 PMC: 11408346. DOI: 10.3389/fcell.2024.1421981.

Exploring the value of FAP-targeted PET/CT in differentiating breast cancer molecular subtypes: a preliminary study.

Liu T, Xu S, Cheng K, Pei J, Wang S, Li C Eur J Nucl Med Mol Imaging. 2024; 52(1):280-290.

PMID: 39133307 DOI: 10.1007/s00259-024-06873-w.

18F-FDG-PET/CT in breast cancer imaging: Restaging and Implications for treatment decisions in a clinical practice setting.

Skarping I Acta Oncol. 2024; 63:669-677.

PMID: 39129250 PMC: 11332462. DOI: 10.2340/1651-226X.2024.40003.

Joint EANM-SNMMI guideline on the role of 2-[F]FDG PET/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA).

Vaz S, Pilkington Woll J, Cardoso F, Groheux D, Cook G, Ulaner G Eur J Nucl Med Mol Imaging. 2024; 51(9):2706-2732.

PMID: 38740576 PMC: 11224102. DOI: 10.1007/s00259-024-06696-9.

Current Role and Future Prospects of Positron Emission Tomography (PET)/Computed Tomography (CT) in the Management of Breast Cancer.

Robson N, Thekkinkattil D Medicina (Kaunas). 2024; 60(2).

PMID: 38399608 PMC: 10889944. DOI: 10.3390/medicina60020321.

References

Koolen B, Vrancken Peeters M, Wesseling J, Lips E, Vogel W, Aukema T . Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2012; 39(12):1830-8. DOI: 10.1007/s00259-012-2211-z. View

Groheux D, Hindie E, Delord M, Giacchetti S, Hamy A, de Bazelaire C . Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer. J Natl Cancer Inst. 2012; 104(24):1879-87. PMC: 3525816. DOI: 10.1093/jnci/djs451. View

Palaskas N, Larson S, Schultz N, Komisopoulou E, Wong J, Rohle D . 18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. Cancer Res. 2011; 71(15):5164-74. PMC: 3148325. DOI: 10.1158/0008-5472.CAN-10-4633. View

Goldhirsch A, Wood W, Gelber R, Coates A, Thurlimann B, Senn H . Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007; 18(7):1133-44. DOI: 10.1093/annonc/mdm271. View

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

Groheux D, Giacchetti S, Moretti J, Porcher R, Espie M, Lehmann-Che J . Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2010; 38(3):426-35. DOI: 10.1007/s00259-010-1640-9. View

Vant Veer L, Paik S, Hayes D . Gene expression profiling of breast cancer: a new tumor marker. J Clin Oncol. 2005; 23(8):1631-5. DOI: 10.1200/JCO.2005.12.005. View

Goldhirsch A, Wood W, Coates A, Gelber R, Thurlimann B, Senn H . Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011; 22(8):1736-47. PMC: 3144634. DOI: 10.1093/annonc/mdr304. View

Avril N, Menzel M, Dose J, Schelling M, Weber W, Janicke F . Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med. 2001; 42(1):9-16. View

10.

Aukema T, Rutgers E, Vogel W, Teertstra H, Oldenburg H, Vrancken Peeters M . The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques. Eur J Surg Oncol. 2009; 36(4):387-92. DOI: 10.1016/j.ejso.2009.11.009. View

11.

Kumar R, Chauhan A, Zhuang H, Chandra P, Schnall M, Alavi A . Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat. 2006; 98(3):267-74. DOI: 10.1007/s10549-006-9159-2. View

12.

Koolen B, Vrancken Peeters M, Aukema T, Vogel W, Oldenburg H, van der Hage J . 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques. Breast Cancer Res Treat. 2011; 131(1):117-26. DOI: 10.1007/s10549-011-1767-9. View

13.

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

14.

Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N . Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol. 2008; 38(4):250-8. DOI: 10.1093/jjco/hyn019. View

15.

Specht J, Kurland B, Montgomery S, Dunnwald L, Doot R, Gralow J . Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer. Clin Cancer Res. 2010; 16(10):2803-10. PMC: 2902373. DOI: 10.1158/1078-0432.CCR-10-0026. View

16.

J van t Veer L, Dai H, van de Vijver M, He Y, Hart A, Mao M . Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415(6871):530-6. DOI: 10.1038/415530a. View

17.

Gianni L, Dafni U, Gelber R, Azambuja E, Muehlbauer S, Goldhirsch A . Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011; 12(3):236-44. DOI: 10.1016/S1470-2045(11)70033-X. View

18.

Hugh J, Hanson J, Chon U Cheang M, Nielsen T, Perou C, Dumontet C . Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol. 2009; 27(8):1168-76. PMC: 2667821. DOI: 10.1200/JCO.2008.18.1024. View

19.

Ueda S, Kondoh N, Tsuda H, Yamamoto S, Asakawa H, Fukatsu K . Expression of centromere protein F (CENP-F) associated with higher FDG uptake on PET/CT, detected by cDNA microarray, predicts high-risk patients with primary breast cancer. BMC Cancer. 2008; 8:384. PMC: 2631591. DOI: 10.1186/1471-2407-8-384. View

20.

Cheang M, Chia S, Voduc D, Gao D, Leung S, Snider J . Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009; 101(10):736-50. PMC: 2684553. DOI: 10.1093/jnci/djp082. View